Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved..
OBJECTIVES: T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants.
METHODS: We recently evaluated a peptide-based SARS-CoV-2 T cell activator termed CoVac-1 in a first-in-human trial in healthy adults. Here, we report on long-term safety and efficacy data of CoVac-1 until month 12.
RESULTS: CoVac-1 is well tolerated without long-term immune-related side effects and induces long-lasting anti-viral T cell responses in 100% of study participants, with potent expandability of clusters of differentiation (CD4+) and CD8+ T cells targeting multiple different CoVac-1 T cell epitopes. T cell responses were associated with stronger injection site reaction. Beyond induction of T cell immunity, 89% of subjects developed CoVac-1-specific immunoglobulin G antibodies which associated with the intensity of the T cell response, indicating that CoVac-1-specific CD4+ T cells support the induction of B-cell responses. Vaccination with approved COVID-19 vaccines boosted CoVac-1-specific T cell responses. Overall, a low SARS-CoV-2 infection rate (8.3%) was observed.
CONCLUSION: Together, a single application of CoVac-1 elicits long-lived and broad SARS-CoV-2-specific T cell immunity, which further supports the current evaluation of our T cell activator in patients with congenital or acquired B-cell defects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 139(2024) vom: 15. Jan., Seite 69-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tandler, Claudia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 15.01.2024 Date Revised 15.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2023.11.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365076724 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365076724 | ||
| 003 | DE-627 | ||
| 005 | 20240115231926.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2023.11.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1260.xml |
| 035 | |a (DE-627)NLM365076724 | ||
| 035 | |a (NLM)38016500 | ||
| 035 | |a (PII)S1201-9712(23)00770-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tandler, Claudia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2024 | ||
| 500 | |a Date Revised 15.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a OBJECTIVES: T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants | ||
| 520 | |a METHODS: We recently evaluated a peptide-based SARS-CoV-2 T cell activator termed CoVac-1 in a first-in-human trial in healthy adults. Here, we report on long-term safety and efficacy data of CoVac-1 until month 12 | ||
| 520 | |a RESULTS: CoVac-1 is well tolerated without long-term immune-related side effects and induces long-lasting anti-viral T cell responses in 100% of study participants, with potent expandability of clusters of differentiation (CD4+) and CD8+ T cells targeting multiple different CoVac-1 T cell epitopes. T cell responses were associated with stronger injection site reaction. Beyond induction of T cell immunity, 89% of subjects developed CoVac-1-specific immunoglobulin G antibodies which associated with the intensity of the T cell response, indicating that CoVac-1-specific CD4+ T cells support the induction of B-cell responses. Vaccination with approved COVID-19 vaccines boosted CoVac-1-specific T cell responses. Overall, a low SARS-CoV-2 infection rate (8.3%) was observed | ||
| 520 | |a CONCLUSION: Together, a single application of CoVac-1 elicits long-lived and broad SARS-CoV-2-specific T cell immunity, which further supports the current evaluation of our T cell activator in patients with congenital or acquired B-cell defects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B-cell deficiency | |
| 650 | 4 | |a Peptide | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T cell immunity | |
| 650 | 4 | |a T cells | |
| 650 | 4 | |a Vaccine | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Peptides |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Heitmann, Jonas S |e verfasserin |4 aut | |
| 700 | 1 | |a Michel, Tanja M |e verfasserin |4 aut | |
| 700 | 1 | |a Marconato, Maddalena |e verfasserin |4 aut | |
| 700 | 1 | |a Jaeger, Simon U |e verfasserin |4 aut | |
| 700 | 1 | |a Tegeler, Christian M |e verfasserin |4 aut | |
| 700 | 1 | |a Denk, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Marion |e verfasserin |4 aut | |
| 700 | 1 | |a Oezbek, Melek Tutku |e verfasserin |4 aut | |
| 700 | 1 | |a Maringer, Yacine |e verfasserin |4 aut | |
| 700 | 1 | |a Schroeder, Sarah M |e verfasserin |4 aut | |
| 700 | 1 | |a Schneiderhan-Marra, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Wiesmüller, Karl-Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Bitzer, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Ruetalo, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Schindler, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Meisner, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Imma |e verfasserin |4 aut | |
| 700 | 1 | |a Rammensee, Hans-Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Salih, Helmut R |e verfasserin |4 aut | |
| 700 | 1 | |a Walz, Juliane S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 139(2024) vom: 15. Jan., Seite 69-77 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2024 |g day:15 |g month:01 |g pages:69-77 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2023.11.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2024 |b 15 |c 01 |h 69-77 | ||